Induction of regulatory T cells and efficacy of low-dose interleukin-2 in systemic sclerosis: interventional open-label phase 1–phase 2a study

Background Systemic sclerosis (SSc) is a chronic autoimmune disease, with impaired immune response, increased fibrosis and endothelial dysfunction. Regulatory T cells (Tregs), which are essential to control inflammation, tissue repair and autoimmunity, have a decreased frequency and impaired functio...

Full description

Bibliographic Details
Published in:	RMD Open
Main Authors:	Michelle Rosenzwajg, Roberta Lorenzon, Patrice Cacoub, Arsène Mekinian, Anne Daguenel-Nguyen, Eric Vicaut, David Klatzmann, Sébastien Rivière, Olivier Fain, François Barde, Carlotta Cacciatore
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2024-05-01
Online Access:	https://rmdopen.bmj.com/content/10/2/e003500.full

Similar Items

Iloprost Duration for Digital Ulcers in Systemic Sclerosis: French Retrospective Study at Two Centers and Literature Review
by: Céline Jamart, et al.
Published: (2022-07-01)

S11.3 Low-dose interleukin-2 therapy in active systemic lupus erythematosus (lupil-2): a multi-center, double-blind, randomized and placebo-controlled phase 2 trial
by: J Smolen, et al.
Published: (2022-10-01)

Interleukin-1 in the Response of Follicular Helper and Follicular Regulatory T Cells
by: Paul-Gydéon Ritvo, et al.
Published: (2019-02-01)

Expression of an interleukin-2 partial agonist enhances regulatory T cell persistence and efficacy in mouse autoimmune models
by: Janie Robert, et al.
Published: (2025-05-01)

Human and mouse CD8+CD25+FOXP3+ regulatory T cells at steady state and during interleukin-2 therapy
by: Guillaume eChurlaud, et al.
Published: (2015-04-01)

Depletion of T regulatory cells through selection of CD127-positive cells results in a population enriched in memory T cells: implications for anti-tumor cell therapy
by: Soumia Touil, et al.
Published: (2012-11-01)

Randomized phase II study of stereotactic body radiotherapy and interleukin-2 versus interleukin-2 in patients with metastatic melanoma
by: Marka Crittenden, et al.
Published: (2020-05-01)

Narcolepsy Type 1 Is Associated with a Systemic Increase and Activation of Regulatory T Cells and with a Systemic Activation of Global T Cells.
by: Michel Lecendreux, et al.
Published: (2017-01-01)

A phase Ib study of interleukin-2 plus pembrolizumab for patients with advanced melanoma
by: Ann W. Silk, et al.
Published: (2023-02-01)

Cardiovascular events in patients with myositis: results from a French retrospective cohort
by: Arsène Mekinian, et al.
Published: (2025-03-01)

Interleukin-2/Anti-Interleukin-2 Immune Complex Expands Regulatory T Cells and Reduces Angiotensin II-Induced Aortic Stiffening
by: Beenish Majeed, et al.
Published: (2014-01-01)

Interleukin-2/Anti-Interleukin-2 Immune Complex Attenuates Cardiac Remodeling after Myocardial Infarction through Expansion of Regulatory T Cells
by: Zhipeng Zeng, et al.
Published: (2016-01-01)

A phase 1 proof-of-concept study evaluating safety, tolerability, and biological marker responses with combination therapy of CTLA4-Ig and interleukin-2 in amyotrophic lateral sclerosis
by: Jason R. Thonhoff, et al.
Published: (2024-06-01)

The regulatory T cell-selective interleukin-2 receptor agonist rezpegaldesleukin in the treatment of inflammatory skin diseases: two randomized, double-blind, placebo-controlled phase 1b trials
by: Jonathan I. Silverberg, et al.
Published: (2024-10-01)

Épinal (Vosges). ZAC de Laufromont – phase 2
by: Sébastien Jeandemange
Published: (2013-12-01)

Interleukin‐2/anti‐interleukin‐2 immune complex attenuates cold ischemia‐reperfusion injury after kidney transplantation by increasing renal regulatory T cells
by: Joon Young Jang, et al.
Published: (2024-03-01)

The Association of -475 and -631 Interleukin-2 Gene Polymorphism with Multiple Sclerosis in Iranian Patients
by: Akbar Akbari, et al.
Published: (2013-01-01)

IL-1β signaling modulates T follicular helper and regulatory cells in human lymphoid tissues
by: Romain Vaineau, et al.
Published: (2025-06-01)

Interleukin-1 regulates follicular T cells during the germinal center reaction
by: Aude Belbezier, et al.
Published: (2024-05-01)

Inflammatory and Immune Disorders Associated with Myelodysplastic Syndromes
by: Vincent Jachiet, et al.
Published: (2021-05-01)

Parental autoimmune and autoinflammatory disorders as multiple risk factors for common neurodevelopmental disorders in offspring: a systematic review and meta-analysis
by: Pierre Ellul, et al.
Published: (2022-03-01)

Targeted regulatory T cell activation by site-specific PEGylated interleukin-2 mitigates autoimmune inflammation
by: Masahiro Ikeda, et al.
Published: (2025-12-01)

Interleukin‐2‐inducible T‐cell kinase (Itk) signaling regulates potent noncanonical regulatory T cells
by: Mahinbanu Mammadli, et al.
Published: (2021-12-01)

Interleukin-2 receptor signaling acts as a checkpoint that influences the distribution of regulatory T cell subsets
by: Acacia N. Shouse, et al.
Published: (2024-12-01)

A phase 1 open-label pilot study of low-dose interleukine-2 immunotherapy in patients with Alzheimer’s disease
by: Alireza Faridar, et al.
Published: (2023-11-01)

A randomised phase 2a study to investigate the effects of blocking interleukin-33 with tozorakimab in patients hospitalised with COVID-19: ACCORD-2
by: Tom Wilkinson, et al.
Published: (2023-10-01)

Safety and tolerability of tegoprubart in patients with amyotrophic lateral sclerosis: A Phase 2A clinical trial.
by: Steven Perrin, et al.
Published: (2024-10-01)

Prevalence and association of placental lesions with obstetrical features and outcome: data from French prospective studyAJOG Global Reports at a Glance
by: Jeremy Boujenah, et al.
Published: (2024-08-01)

The Association of −330 Interleukin-2 Gene Polymorphism with Its Plasma Concentration in Iranian Multiple Sclerosis Patients
by: Arezou Sayad, et al.
Published: (2014-01-01)

Treatment of chronic hepatitis C-associated cryoglobulinemia vasculitis at the era of direct-acting antivirals
by: Cloé Comarmond, et al.
Published: (2020-07-01)

IL2RA genetic heterogeneity in multiple sclerosis and type 1 diabetes susceptibility and soluble interleukin-2 receptor production.
by: Lisa M Maier, et al.
Published: (2009-01-01)

Interleukins in Platelet Biology: Unraveling the Complex Regulatory Network
by: Miao Huang, et al.
Published: (2024-01-01)

Chronic Myelomonocytic Leukemia Patients With Lysozyme Nephropathy and Renal Infiltration Display Markers of Severe Disease
by: Marie-Camille Lafargue, et al.
Published: (2023-12-01)

Systemic sclerosis associated interstitial lung disease: a survey of current practices in France
by: Amélie Nicolas, et al.
Published: (2023-05-01)

Combinatorial therapy with two pro-coagulants and one osmotic agent reduces the extent of the lesion in the acute phase of spinal cord injury in the rat
by: Mathieu Boutonnet, et al.
Published: (2017-12-01)

Regulatory design governing progression of population growth phases in bacteria.
by: Agustino Martínez-Antonio, et al.
Published: (2012-01-01)

DAMA/LIBRA-phase1 results and perspectives of the phase2
by: Bernabei R., et al.
Published: (2015-01-01)

Salivary Levels of Interleukin-23 in Iranian Patients with Systemic Sclerosis
by: Ali Tadayon, et al.
Published: (2024-06-01)

Salivary Levels of Interleukin-17 in Iranian Patients With Systemic Sclerosis
by: Ali Tadayon, et al.
Published: (2024-12-01)

Contribution of B-lymphocytes to the production of Interleukin-17 in multiple sclerosis
by: N. V. Sursyakova, et al.
Published: (2023-08-01)